KOREA WHO
-
-
-
CEO of JW Pharmaceutical
Shin Young-seop
Sales Expert Secures Fourth Term, Expands Pipeline Portfolio
-
Last Updated on Apr 22, 2026
-
CEO of JW Pharmaceutical
Life Summary
Shin Young-seop is the CEO of JW Pharmaceutical.
He is accelerating the shift to a research and development-centered business structure while focusing on clinical progress in key pipelines and portfolio expansion.
He was born on October 5, 1963.
He graduated from Chung-Ang University with a degree in trade and joined JW Pharmaceutical.
After serving as branch sales manager, head of the sales division, and head of the pharmaceutical business division, he was appointed CEO in 2017.
He is a “one-club man” who has spent nearly 40 years at JW Pharmaceutical and is now in his 10th full year as CEO.
Coming from the sales division, he has a deep understanding of the pharmaceutical field.
He has earned the trust of the owner family, as shown by his fourth consecutive reappointment in 2026.
He is also carrying the burden of judicial risk over a violation of the Pharmaceutical Affairs Act.
#JWPharmaceutical #ShinYoungseop #pharmaceuticalindustry #RND #drugpipeline #portfolioexpansion #CEOprofile #Koreapharma #clinicaldevelopment #PharmaceuticalAffairsAct
He is accelerating the shift to a research and development-centered business structure while focusing on clinical progress in key pipelines and portfolio expansion.
He was born on October 5, 1963.
He graduated from Chung-Ang University with a degree in trade and joined JW Pharmaceutical.
After serving as branch sales manager, head of the sales division, and head of the pharmaceutical business division, he was appointed CEO in 2017.
He is a “one-club man” who has spent nearly 40 years at JW Pharmaceutical and is now in his 10th full year as CEO.
Coming from the sales division, he has a deep understanding of the pharmaceutical field.
He has earned the trust of the owner family, as shown by his fourth consecutive reappointment in 2026.
He is also carrying the burden of judicial risk over a violation of the Pharmaceutical Affairs Act.
#JWPharmaceutical #ShinYoungseop #pharmaceuticalindustry #RND #drugpipeline #portfolioexpansion #CEOprofile #Koreapharma #clinicaldevelopment #PharmaceuticalAffairsAct